Literature DB >> 15714752

Species differences in platelet responses to thrombin and SFLLRN. receptor-mediated calcium mobilization and aggregation, and regulation by protein kinases.

C K Derian1, R J Santulli, K A Tomko, B J Haertlein, P Andrade-Gordon.   

Abstract

The thrombin receptor on human platelets is activated by thrombin to stimulate platelet aggregation through the tethered ligand SFLLRN. This study examined the effects of thrombin and SFLLRN on aggregation and calcium mobilization ([Ca2+]i) in rat, guinea pig, rabbit, dog, monkey, and human platelets, and the role of protein kinases in regulating these functions. Thrombin induced platelet aggregation and [Ca2+]i in all species studied; however, only guinea pig, monkey and human platelets were responsive to SFLLRN. Similar species specific effects were obtained with [Ca2+]i studies. The kinetic profile for [Ca2+]i differed among species, suggesting that regulatory mechanisms for calcium differed between agonists and among species. Staurosporine, a non-selective inhibitor of protein kinases, inhibited platelet aggregation induced by thrombin or SFLLRN in all species. Staurosporine inhibited thrombin-induced [Ca2+]i in guinea pigs, had no effect in rat, and increased [Ca2+]i in all other species. Staurosporine inhibited SFLLRN-induced [Ca2+]i in guinea pig, yet had no effect in monkey or human. Tyrphostin 23, a specific inhibitor of tyrosine protein kinases, inhibited thrombin-induced aggregation of rabbit, monkey, dog and human platelets. SFLLRN-induced aggregation was also inhibited by tyrphostin 23. Tyrphostin 23 inhibited [Ca2+]i induced by either thrombin or SFLLRN in all species. Based on the differential response to agonist stimulation, we propose that thrombin can activate platelets via SFLLRN-dependent and independent mechanisms, which could involve yet unrecognized subtypes of the thrombin receptor or distinct cellular activating mechanisms. Furthermore, differential regulation of calcium mobilization and aggregation was observed in those platelets responding to either thrombin or SFLLRN.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 15714752     DOI: 10.1016/0049-3848(95)00084-5

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  7 in total

Review 1.  How the protease thrombin talks to cells.

Authors:  S R Coughlin
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

2.  Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin.

Authors:  M L Kahn; M Nakanishi-Matsui; M J Shapiro; H Ishihara; S R Coughlin
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

Review 3.  Cell-based screening: extracting meaning from complex data.

Authors:  Steven Finkbeiner; Michael Frumkin; Paul D Kassner
Journal:  Neuron       Date:  2015-04-08       Impact factor: 17.173

4.  Protease-activated receptor-1 impedes prostate and intestinal tumor progression in mice.

Authors:  G N Adams; B K Sharma; L Rosenfeldt; M Frederick; M J Flick; D P Witte; L O Mosnier; E Harmel-Laws; K A Steinbrecher; J S Palumbo
Journal:  J Thromb Haemost       Date:  2018-09-27       Impact factor: 5.824

Review 5.  Post-Traumatic Epilepsy and Comorbidities: Advanced Models, Molecular Mechanisms, Biomarkers, and Novel Therapeutic Interventions.

Authors:  Victoria M Golub; Doodipala Samba Reddy
Journal:  Pharmacol Rev       Date:  2022-04       Impact factor: 25.468

Review 6.  Modeling trauma in rats: similarities to humans and potential pitfalls to consider.

Authors:  Birte Weber; Ina Lackner; Melanie Haffner-Luntzer; Annette Palmer; Jochen Pressmar; Karin Scharffetter-Kochanek; Bernd Knöll; Hubert Schrezenemeier; Borna Relja; Miriam Kalbitz
Journal:  J Transl Med       Date:  2019-09-05       Impact factor: 5.531

7.  Platelet specific promoters are insufficient to express protease activated receptor 1 (PAR1) transgene in mouse platelets.

Authors:  Amal Arachiche; María de la Fuente; Marvin T Nieman
Journal:  PLoS One       Date:  2014-05-15       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.